Dr. Morris on Challenges of Radium-223 Treatment in Prostate Cancer

Michael J. Morris, MD
Published: Wednesday, Feb 22, 2017



Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer.

In a phase I/IIa clinical trial evaluating the effects of radium-223 with docetaxel versus docetaxel alone on bone biomarkers, patients who received the combination regimen had a greater decline in tALP and bone formation markers bALP and P1NP.

It is particularly difficult to determine whether or not patients are deriving benefit from radium-223 treatment, says Morris. This is because the usual consideration of prostate-specific antigen testing doesn’t apply.

According to Morris, this highlights the importance for bone biomarkers and following patients throughout treatment.

Next steps include evaluating this regimen’s relationship to survival in a phase III trial.
 


Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer.

In a phase I/IIa clinical trial evaluating the effects of radium-223 with docetaxel versus docetaxel alone on bone biomarkers, patients who received the combination regimen had a greater decline in tALP and bone formation markers bALP and P1NP.

It is particularly difficult to determine whether or not patients are deriving benefit from radium-223 treatment, says Morris. This is because the usual consideration of prostate-specific antigen testing doesn’t apply.

According to Morris, this highlights the importance for bone biomarkers and following patients throughout treatment.

Next steps include evaluating this regimen’s relationship to survival in a phase III trial.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x